<--- Back to Details
First PageDocument Content
Organofluorides / Pharmacology / Integrase inhibitors / Tenofovir / Emtricitabine / Gilead / Cobicistat / Elvitegravir / GS / Gilead Sciences / Chemistry / Organic chemistry
Date: 2013-02-24 13:40:20
Organofluorides
Pharmacology
Integrase inhibitors
Tenofovir
Emtricitabine
Gilead
Cobicistat
Elvitegravir
GS
Gilead Sciences
Chemistry
Organic chemistry

Add to Reading List

Source URL: www.gilead.com

Download Document from Source Website

File Size: 85,96 KB

Share Document on Facebook

Similar Documents

Microbiology / HIV/AIDS / Virology / Integrase / HIV / Nef / Management of HIV/AIDS / Zidovudine / Retrovirus / Discovery and development of integrase inhibitors / Discovery and development of HIV-protease inhibitors

June 17, 2009  Chemicals Targeting an HIV‐1 Nef/Host Cell Kinase Complex as Novel Anti‐ Retroviral Compounds    Damilola A. Adepegba, Department of Natural Sciences, University of Maryland 

DocID: 1qLnJ - View Document

Organofluorides / Pharmacology / Integrase inhibitors / Tenofovir / Emtricitabine / Gilead / Cobicistat / Elvitegravir / GS / Gilead Sciences / Chemistry / Organic chemistry

GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a reasonable testing program, the product referenced in this certificate complies with applicable regulations

DocID: 1aVDG - View Document

Intel Viiv / Integrase inhibitors / Organofluorides / Pfizer / Biology / Pharmacology / Dolutegravir / Shionogi / Pharmaceutical industry / Pharmaceutical sciences / ViiV Healthcare / GlaxoSmithKline

Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav

DocID: 1ai1w - View Document

Medicine / HIV/AIDS / Cyclopropanes / Integrase inhibitors / Amides / Lamivudine / Zidovudine / Antiretroviral drug / GlaxoSmithKline / Chemistry / Organic chemistry / Organofluorides

Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 S

DocID: 1a5kT - View Document

Organic chemistry / Health / HIV/AIDS / Amides / Oxadiazoles / Raltegravir / Lamivudine / GlaxoSmithKline / Dolutegravir / Organofluorides / Chemistry / Integrase inhibitors

  Once‐Daily Dolutegravir is Non‐Inferior to Twice‐Daily Raltegravir  in Treatment‐Naïve Adults with HIV‐1    

DocID: 1a5bW - View Document